64.225.110.72.sslip.io
Open in
urlscan Pro
64.225.110.72
Public Scan
URL:
https://64.225.110.72.sslip.io/
Submission: On August 10 via api from US — Scanned from US
Submission: On August 10 via api from US — Scanned from US
Form analysis 2 forms found in the DOM
GET https://www.iavi.org/
<form role="search" method="get" id="searchform" class="searchform" action="https://www.iavi.org/">
<div>
<label class="screen-reader-text" for="s">Search for:</label>
<input type="text" value="" name="s" id="s">
<input type="submit" id="searchsubmit" value="Search">
</div>
</form>Name: mc-embedded-subscribe-form — POST https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&id=bfee2c6c82&f_id=00d0dce4f0
<form action="https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&id=bfee2c6c82&f_id=00d0dce4f0" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank"
novalidate="novalidate">
<div id="mc_embed_signup_scroll">
<h2>Subscribe</h2>
<p>Use this form to receive updates on IAVI‘s work and the latest news from the field.</p>
<div class="mc-field-group">
<label for="mce-FNAME" class="mc-label-ghost">First Name</label>
<input type="text" name="FNAME" class="required text" required="" id="mce-FNAME" value="" placeholder="First Name *" aria-required="true">
</div>
<div class="mc-field-group">
<label for="mce-LNAME" class="mc-label-ghost">Last Name</label>
<input type="text" name="LNAME" class="required text" id="mce-LNAME" value="" required="" placeholder="Last Name *" aria-required="true">
</div>
<div class="mc-field-group"><label for="mce-EMAIL" class="mc-label-ghost">E-mail Address</label><input type="email" name="EMAIL" class="required email" id="mce-EMAIL" value="" required="" placeholder="E-mail Address *" aria-required="true"></div>
<div class="mc-field-group input-group">
<h2>Subscription Type </h2>
<ul>
<li><input type="checkbox" name="group[80579][1]" id="mce-group[80579]-80579-0" value=""><label for="mce-group[80579]-80579-0">IAVI Updates<span>Periodic updates on recent advances in biomedical innovations, policy initiatives, funding
updates, stories from the field, and IAVI’s Discovery Newsletter.</span></label></li>
<li><input type="checkbox" name="group[80579][2]" id="mce-group[80579]-80579-1" value=""><label for="mce-group[80579]-80579-1">IAVI Report<span>A publication covering the latest scientific and policy research in the quest to develop vaccines,
antibodies, and other biomedical innovations to combat the spread of HIV and other infectious diseases.</span></label></li>
</ul>
</div>
<div id="mce-responses" class="clear">
<div class="response" id="mce-error-response" style="display: none;"></div>
<div class="response" id="mce-success-response" style="display: none;"></div>
</div>
<div aria-hidden="true" style="position: absolute; left: -5000px;"><label for="hidden-mc-element">by Mailchimp</label><input type="text" name="b_65ad404c928bcb0edfd984a08_bfee2c6c82" id="hidden-mc-element" tabindex="-1" value=""></div>
<div class="clear"><input type="submit" name="subscribe" id="mc-embedded-subscribe" class="button button--primary" value="Subscribe"></div>
</div>
</form>Text Content
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store
and/or access device information. Consenting to these technologies will allow us
to process data such as browsing behavior or unique IDs on this site. Not
consenting or withdrawing consent, may adversely affect certain features and
functions.
Functional Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose
of enabling the use of a specific service explicitly requested by the subscriber
or user, or for the sole purpose of carrying out the transmission of a
communication over an electronic communications network.
Preferences Preferences
The technical storage or access is necessary for the legitimate purpose of
storing preferences that are not requested by the subscriber or user.
Statistics Statistics
The technical storage or access that is used exclusively for statistical
purposes. The technical storage or access that is used exclusively for anonymous
statistical purposes. Without a subpoena, voluntary compliance on the part of
your Internet Service Provider, or additional records from a third party,
information stored or retrieved for this purpose alone cannot usually be used to
identify you.
Marketing Marketing
The technical storage or access is required to create user profiles to send
advertising, or to track the user on a website or across several websites for
similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about
these purposes
Accept Deny View preferences Save preferences View preferences
Cookie Policy {title} {title}
IAVI Skip to content
Menu Close
Back to Main Menu
* Our Work
* Research & Development
* Discovery
* Epidemiology
* Clinical Development
* Product Development
* Global Access
* Advocacy & Community Engagement
* Health Areas
* Pipeline
* HIV Vaccines
* HIV Antibodies
* Tuberculosis
* Emerging Infectious Diseases
* About
* About IAVI
* About IAVI
* Our Story
* Careers
* Diversity, Equity, & Inclusion
* Financial Statements
* Contact us
* Regions
* Africa
* Europe
* India
* United States
* Leadership
* Board of Directors
* Senior Leadership
* Funders & Partners
* Funders
* Partnerships
* Media & Resources
* News & Press
* Features
* Press Releases
* In The News
* Digital Media
* Videos
* Podcasts
* Resources
* IAVI Report
* Scientific Publications
* Vaccine Literacy Library
* Fact Sheets & Publications
Search
Close
Search for:
* Quick Links
* Our Work
* Emerging Infectious Diseases
* Pipeline
* Senior Leadership
* Trending Now
* HIV Vaccines
* HIV Antibodies
* Tuberculosis
AFFORDABLE, ACCESSIBLE VACCINES & ANTIBODIES
We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.
About us
OUR APPROACH
--------------------------------------------------------------------------------
We take a full-circle approach to product development, from the grassroots level
to the lab to legislative bodies.
MISSION
--------------------------------------------------------------------------------
To translate scientific discoveries into affordable, globally accessible public
health solutions.
VISION
--------------------------------------------------------------------------------
A world where all people have equitable access to innovative vaccines and
therapeutics.
OUR HEALTH AREAS
* HIV
* Tuberculosis
* Lassa fever
* Marburg virus
* Sudan Ebolavirus
* COVID-19
HIV
THE CHALLENGE
HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million
people acquiring HIV in 2023. Given the complexities of HIV, traditional
approaches to vaccine development have so far failed to result in a vaccine that
provides protection against HIV. However, a vaccine is still needed to bring a
true end to the HIV pandemic. Source: UNAIDS
OUR SOLUTION
IAVI scientists and our collaborators are developing next-generation HIV
vaccines to address the challenges of HIV vaccine design. Together, we have
pioneered promising new vaccination strategies and the discovery of broadly
neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are
developing HIV bnAbs to prevent HIV acquisition while we advance vaccine
candidates.
TUBERCULOSIS
THE CHALLENGE
Tuberculosis (TB) is the world’s leading infectious disease killer. In 2022,
10.6 million people fell ill with TB and 1.3 million people died of TB disease.
The only available TB vaccine is the century-old Bacille Calmette-Guérin, or
BCG. While this vaccine has efficacy in protecting against severe TB disease in
infants and young children, it is largely ineffective in adolescents and adults,
among whom most transmission and disease occurs. Source: WHO
OUR SOLUTION
IAVI works across our global hubs with a diverse network of partners to advance
the most promising TB vaccine candidates from discovery through clinical trials,
and eventually, to post-licensure access. Our work extends to policy and
advocacy initiatives that support TB vaccine development and access in regions
where new vaccines are needed most.
LASSA FEVER
THE CHALLENGE
Lassa fever is an acute viral hemorrhagic illness endemic to West Africa that
causes significant annual outbreaks of disease. Lassa fever is difficult to
diagnose, and surveillance data is limited. Current estimates range from 300,000
to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for
Lassa fever exist. Source: WHO
OUR SOLUTION
IAVI is developing a single-dose vaccine candidate for Lassa that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine
candidate was well tolerated and immunogenic over a wide dose range in a Phase I
clinical study. IAVI also conducts Lassa epidemiological studies and modeling to
support future vaccine access.
MARBURG VIRUS
THE CHALLENGE
Marburg virus is a filovirus and the causative agent of Marburg virus disease
(MVD), which has a case fatality ratio of up to 88%. Marburg virus has the
capacity to cause outbreaks with high fatality rates and is a potential
bioterror threat. No vaccines or antiviral treatments are approved for MVD. A
Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO
OUR SOLUTION
IAVI is developing a vaccine candidate for Marburg that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine, which is now approved
by the U.S. FDA and registered for use in several African countries. Preclinical
data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in
an animal model with one dose.
SUDAN EBOLAVIRUS
THE CHALLENGE
Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most
recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan
ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine
for Ebola Zaire virus does not provide cross protection against the Sudan
strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to
future outbreaks. Source: WHO
OUR SOLUTION
IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a
recombinant vesicular stomatitis virus (rVSV) vector similar to the technology
underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak
in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a
planned ring vaccination trial. While the trial did not go forward due to
outbreak control, IAVI has continued clinical development to prepare for future
outbreaks.
COVID-19
THE CHALLENGE
Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths
have been recorded worldwide, but the actual number is thought to be higher.
While highly effective, approved COVID-19 vaccines do not fully block
transmission or breakthrough infection. Additional COVID-19 vaccines continue to
be an urgent need, particularly vaccines suitable for widespread use in middle
and low-income countries. Source: WHO
OUR SOLUTION
IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant
vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated
safety in humans when administered intramuscularly and has been produced at
scale to support larger future clinical trials. IAVI is also investigating an
intranasal formulation of our COVID-19 vaccine candidate to prevent infection.
OUR IMPACT
--------------------------------------------------------------------------------
WE CONDUCT PRECLINICAL AND CLINICAL TRIALS OF OUR OWN VACCINES AND ANTIBODIES.
OUR FOCUS IS ON DISEASES OF GLOBAL IMPORTANCE FOR WHICH THERE IS NO MARKET AND
LITTLE FINANCIAL INCENTIVE FOR DEVELOPMENT. WE ALSO COLLABORATE WITH AND SUPPORT
OTHER SCIENTIFIC ORGANIZATIONS TO CONDUCT THEIR OWN CLINICAL TRIALS OF PRIORITY
DISEASE PREVENTION AND THERAPEUTIC INTERVENTIONS.
--------------------------------------------------------------------------------
255 partners from academic, biotech, pharma sectors, civil society, and global
health initiatives
--------------------------------------------------------------------------------
53 biologics candidates supported by the IAVI Product Development Center, out of
which 25 advanced to clinical trials
--------------------------------------------------------------------------------
70,000 volunteers enrolled in observational epidemiology studies
OUR LOCATIONS
--------------------------------------------------------------------------------
IAVI AFRICA
* Cape Town Office, South Africa
* Nairobi Office, Kenya
IAVI EUROPE
* Amsterdam Office, The Netherlands
* Human Immunology Lab, London, U.K.
IAVI INDIA
* Gurugram, Haryana Office
* Antibody Translational Research Program, IAVI-THSTI, Faridabad
IAVI U.S.
* New York Office
* Vaccine Design & Development Lab, New York
* Neutralizing Antibody Center, California
RECENT NEWS & MEDIA
Previous Next
IAVI Report
ANOTHER INFLECTION POINT IN THE HIV/AIDS RESPONSE
July 31, 2024
This part of the story may sound all too familiar. Just before the opening of
the International AIDS Society’s (IAS) 25th International AIDS Conference in
Munich, Germany, the Joint United Nations Programme on HIV/AIDS (UNAIDS)
released their latest global HIV/AIDS statistics. The report shows that 1.3
million people worldwide were newly infected with HIV in […]
Read More
Video
AIDS 2024 WRAP-UP
July 29, 2024
IAVI was at the heart of global HIV/AIDS response dialogue during the 25th
International AIDS Conference in Munich. With more than 40 oral abstract
sessions, 50 invited-speaker sessions, 20 workshops, 30 symposia sessions, 100
satellite sessions, and 2,200 posters, AIDS 2024 showcased exciting
community-led innovations alongside scientific breakthroughs and game changers.
Read More
IAVI Report
THE TIES THAT BIND
July 23, 2024
As thousands gather this week for the 25th International AIDS Conference in
Munich, Germany, participants will be looking for the threads that tie together
a quarter of a century of HIV/AIDS and the latest advances in treatment,
prevention, and cure research. Something critical to the progress in battling
this disease over the last 25 years […]
Read More
Features
LOOKING AHEAD TO ONE OF OUR BUSIEST WEEKS OF THE YEAR: IAVI AT THE INTERNATIONAL
AIDS CONFERENCE
July 15, 2024
IAVI is looking forward to a busy and exciting week at the International AIDS
conference, taking place July 22-26 in Munich, Germany. IAVI leaders will
participate in a range of sessions, including IAVI-organized satellite sessions,
posters, a pre-conference session, and, of course, many side meetings. Some
highlights of IAVI’s upcoming participation include: We welcome you […]
Read More
Features
IAVI SIGNS LEASE ON NEW VACCINE DESIGN AND DEVELOPMENT LAB IN JERSEY CITY, NJ
July 10, 2024
IAVI is pleased to announce that we have signed a lease on a new Vaccine Design
and Development Lab (DDL) space in Jersey City, NJ. Construction has already
begun on the 29,782 sq. ft. space within a lab-ready life sciences building at
95 Greene Street and is slated for completion in early 2025. The DDL […]
Read More
Features
UNITAID, IAVI, MEDICINES PATENT POOL, AND WELLCOME PUBLISH NOVEL APPROACHES TO
ENABLE EQUITABLE ACCESS TO MONOCLONAL ANTIBODIES IN LOW- AND MIDDLE-INCOME
COUNTRIES
July 05, 2024
Unitaid, IAVI, the Medicines Patent Pool and Wellcome proudly announced the
publication of “Novel Approaches to Enable Equitable Access to Monoclonal
Antibodies in Low- and Middle-Income Countries” in PLoS Global Public Health. A
collaborative effort across IAVI’s lead author Shelly Malhotra, vice president
for global access and external affairs, and co-authors from partner
organizations, the article draws on a multistakeholder consultation, to address
critical barriers and proposes innovative strategies to enable equitable access
to monoclonal antibodies (mAbs) in low- and middle-in
Read More
When women are given the opportunity to lead in science, they bring a unique
perspective that is invaluable to the field. This is not just a matter of
equality; it’s a matter of unleashing the full potential of science. Women
leaders in science bring a fresh perspective to the field that is essential for
driving innovation and progress.
Kawela Mumba-Mwangelwa
Graduate of IAVI’s Leadership Development Program, Co-principal Investigator at
the Center for Family Health Research in Zambia
We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.
* Instagram
* YouTube
* Facebook
* LinkedIn
QUICK LINKS
--------------------------------------------------------------------------------
Careers
HIV Vaccines
HIV Antibodies
Tuberculosis
Emerging Infectious Diseases
CONTACT US
--------------------------------------------------------------------------------
IAVI U.S.
125 Broad Street, 9th Floor
New York, NY 10004
USAT: +1.212.847.1111
F: +1.212.847.1112
Contact us Diversity, Equity, & Inclusion Privacy Policy Terms of Use Compliance
& RFPs
©2024 International AIDS Vaccine Initiative. International AIDS Vaccine
Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the
International AIDS Vaccine Initiative, Inc.
SUBSCRIBE
Use this form to receive updates on IAVI‘s work and the latest news from the
field.
First Name
Last Name
E-mail Address
SUBSCRIPTION TYPE
* IAVI UpdatesPeriodic updates on recent advances in biomedical innovations,
policy initiatives, funding updates, stories from the field, and IAVI’s
Discovery Newsletter.
* IAVI ReportA publication covering the latest scientific and policy research
in the quest to develop vaccines, antibodies, and other biomedical
innovations to combat the spread of HIV and other infectious diseases.
by Mailchimp
Manage consent